Biote (BTMD) Current Deferred Revenue (2021 - 2026)

Biote (BTMD) has reported Current Deferred Revenue for 6 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 6.19% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (down 6.19% YoY), while the FY2025 annual figure was $3.0 million, up 1.89% from the prior year.
• Current Deferred Revenue came in at $2.8 million for Q1 2026 at Biote, down from $3.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $3.2 million in Q3 2025, with the low at $1.9 million in Q2 2022.
• Average Current Deferred Revenue over 5 years is $2.7 million, with a median of $2.9 million recorded in 2024.
• Across the five-year window, Current Deferred Revenue jumped 52.77% in 2023 and declined 6.19% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $2.0 million in 2022, then surged by 52.77% to $3.0 million in 2023, then decreased by 1.37% to $3.0 million in 2024, then gained by 1.89% to $3.0 million in 2025, then decreased by 5.6% to $2.8 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $2.8 million, $3.0 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.